Paclitaxel docosahexaenoic acid
- Generic Name
- Paclitaxel docosahexaenoic acid
- Drug Type
- Small Molecule
- Chemical Formula
- C69H81NO15
- CAS Number
- 199796-52-6
- Unique Ingredient Identifier
- OJE5810C4F
- Background
A combination of docosahexaenoic Acid (a natural fatty acid) and paclitaxel (an anticancer drug) being studied in the treatment of cancer. It is a type of mitotic inhibitor.
- Indication
Investigated for use/treatment in breast cancer, colorectal cancer, gastric cancer, kidney cancer, lung cancer, pancreatic cancer, prostate cancer, and skin cancer.
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver
- First Posted Date
- 2007-01-17
- Last Posted Date
- 2017-05-10
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 13
- Registration Number
- NCT00422877
- Locations
- 🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
Taxoprexin Treatment for Advanced Skin Melanoma
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00249262
Taxoprexin® Treatment for Advanced Eye Melanoma
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2018-01-24
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00244816
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
- First Posted Date
- 2005-10-25
- Last Posted Date
- 2018-01-26
- Lead Sponsor
- American Regent, Inc.
- Target Recruit Count
- 519
- Registration Number
- NCT00243867
- Locations
- 🇺🇸
US Oncology, Dallas, Texas, United States
DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-01-15
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- Theradex
- Registration Number
- NCT00024401
- Locations
- 🇺🇸
Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Veterans Affairs Medical Center - East Orange, East Orange, New Jersey, United States
Chemotherapy in Treating Patients With Metastatic Kidney Cancer
- Conditions
- Kidney Cancer
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- Theradex
- Registration Number
- NCT00024388
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
🇺🇸Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
DHA-Paclitaxel in Treating Patients With Metastatic Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2009-02-18
- Lead Sponsor
- Theradex
- Registration Number
- NCT00024375
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Virginia Mason Medical Center, Seattle, Washington, United States
DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- Theradex
- Registration Number
- NCT00024414
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.